Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
- 1 November 2004
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 104 (9) , 2661-2666
- https://doi.org/10.1182/blood-2004-04-1319
Abstract
Cytogenetic abnormalities, evaluated either by karyotype or by fluorescence in situ hybridization (FISH), are considered the most important prognostic factor in multiple myeloma (MM). However, there is no information about the prognostic impact of genomic changes detected by comparative genomic hybridization (CGH). We have analyzed the frequency and prognostic impact of genetic changes as detected by CGH and evaluated the relationship between these chromosomal imbalances and IGH translocation, analyzed by FISH, in 74 patients with newly diagnosed MM. Genomic changes were identified in 51 (69%) of the 74 MM patients. The most recurrent abnormalities among the cases with genomic changes were gains on chromosome regions 1q (45%), 5q (24%), 9q (24%), 11q (22%), 15q (22%), 3q (16%), and 7q (14%), while losses mainly involved chromosomes 13 (39%), 16q (18%), 6q (10%), and 8p (10%). Remarkably, the 6 patients with gains on 11q had IGH translocations. Multivariate analysis selected chromosomal losses, 11q gains, age, and type of treatment (conventional chemotherapy vs autologous transplantation) as independent parameters for predicting survival. Genomic losses retained the prognostic value irrespective of treatment approach. According to these results, losses of chromosomal material evaluated by CGH represent a powerful prognostic factor in MM patients. (Blood. 2004;104:2661-2666)Keywords
This publication has 31 references indexed in Scilit:
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myelomaBlood, 2003
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionBlood, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridizationGenes, Chromosomes and Cancer, 1999
- IL‐4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphasesBritish Journal of Haematology, 1998
- MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMALBritish Journal of Haematology, 1996
- Quantitative analysis of comparative genomic hybridizationCytometry, 1995
- Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid TumorsScience, 1992